Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

by Gray, Jhanelle E , Daniel, Davey , Quantin, Xavier , Ostoros, Gyula , Hui, Rina , Kubota, Kaoru , Cho, Byoung C , Villegas, Augusto , Antonia, Scott J , Huang, Yifan , de Wit, Maike , Tokito, Takaaki , Chiappori, Alberto , Jiang, Haiyi , Bourhaba, Maryam , Kim, Young-Chul , Paz-Ares, Luis , Mekhail, Tarek , de Castro Carpeño, Javier , Melillo, Giovanni , Planchard, David , Yokoi, Takashi , Hiret, Sandrine , Wadsworth, Catherine , Vicente, David , Dennis, Phillip A , Özgüroğlu, Mustafa , Lee, Ki H , Karapetis, Christos S , Murakami, Shuji

in Adult / Aged / Aged, 80 and over / Antibodies, Monoclonal - adverse effects / Antibodies, Monoclonal - therapeutic use / Antibodies, Monoclonal/adverse effects/therapeutic use / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Antineoplastic Agents/adverse effects/therapeutic use / Apoptosis / B7-H1 Antigen - antagonists & inhibitors / Cancer / Cancer therapies / Carcinoma, Non-Small-Cell Lung - mortality / Carcinoma, Non-Small-Cell Lung - secondary / Carcinoma, Non-Small-Cell Lung - therapy / Carcinoma, Non-Small-Cell Lung/mortality/secondary/therapy / Chemoradiotherapy / Chemotherapy / Death / Disease-Free Survival / Drug dosages / Female / Human health and pathology / Human health sciences / Humans / Immunotherapy / Intention to Treat Analysis / Kaplan-Meier Estimate / Life Sciences / Ligands / Lung cancer / Lung diseases / Lung Neoplasms - mortality / Lung Neoplasms - pathology / Lung Neoplasms - therapy / Lung Neoplasms/mortality/pathology/therapy / Male / Medical prognosis / Medical research / Metastases / Middle Aged / Monoclonal antibodies / Neoplasm Staging / Non-small cell lung carcinoma / Oncologie / Oncology / Platinum / Radiation therapy / Sciences de la santé humaine / Targeted cancer therapy / Tumors

2017

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

2017

Confirm

Do you wish to request the book?

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

2017

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Gray, Jhanelle E,

Daniel, Davey,

Quantin, Xavier,

Ostoros, Gyula,

Hui, Rina,

Kubota, Kaoru,

Cho, Byoung C,

Villegas, Augusto,

Antonia, Scott J,

Huang, Yifan,

de Wit, Maike,

Tokito, Takaaki,

Chiappori, Alberto,

Jiang, Haiyi,

Bourhaba, Maryam,

Kim, Young-Chul,

Paz-Ares, Luis,

Mekhail, Tarek,

de Castro Carpeño, Javier,

Melillo, Giovanni,

Planchard, David,

Yokoi, Takashi,

Hiret, Sandrine,

Wadsworth, Catherine,

Vicente, David,

Dennis, Phillip A,

Özgüroğlu, Mustafa,

Lee, Ki H,

Karapetis, Christos S,

Murakami, Shuji

2017

Overview

Relapse is common in patients with locally advanced unresectable lung cancer after concurrent chemotherapy and radiation therapy. In a randomized study, addition of the anti–PD-L1 antibody durvalumab every 2 weeks for 12 months increased relapse-free survival by 47%.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Aged, 80 and over

/ Antibodies, Monoclonal - adverse effects

/ Antibodies, Monoclonal - therapeutic use

/ Antibodies, Monoclonal/adverse effects/therapeutic use

/ Antineoplastic Agents - adverse effects